Vaxart appoints Elaine J. Heron to Board; Julie Cherrington resigns

Vaxart, Inc.

Julie Cherrington, Ph.D. resigned from Vaxart Board effective August 25, 2022.
Elaine J. Heron, Ph.D. appointed to Board, will serve on Audit and Science & Technology Committees.
Dr. Heron is independent; also serves on boards of BioMarin, Palvella, Visgenx, and Watershed Medical.
Michael J. Finney appointed Chair of Science & Technology Committee; W. Mark Watson to Compensation Committee.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elaine J. Heron

Director

VXRT · Vaxart, Inc.

Effective: 2022-08-25
Filed: August 25, 2022, 7:59 PM ET

on August 25, 2022, the Board appointed Elaine J. Heron, Ph.D., to serve on the Board to fill the vacancy caused by Dr. Cherrington’s resignation

Departed

Julie Cherrington

Director

VXRT · Vaxart, Inc.

Effective: 2022-08-25
Successor: Elaine J. Heron
Filed: August 25, 2022, 7:59 PM ET

On August 23, 2022, Julie Cherrington, Ph.D. resigned from the Board of Directors (the “ Board ”) of Vaxart, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elaine J. Heron was appointed as Director at Vaxart, Inc..

Action: appointed
Role: Director

Exact text from the filing

on August 25, 2022, the Board appointed Elaine J. Heron, Ph.D., to serve on the Board to fill the vacancy caused by Dr. Cherrington’s resignation

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Julie Cherrington resigned as Director at Vaxart, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 23, 2022, Julie Cherrington, Ph.D. resigned from the Board of Directors (the “ Board ”) of Vaxart, Inc.

View on SEC.gov

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-021345

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.